(+) NEJM Publication of Phase III Achondroplasia Data - NDA Submission in Q3:26

Research evidence excerpt

(+) NEJM Publication of Phase III Achondroplasia Data - NDA Submission in Q3:26

BridgeBio Pharma, Inc. (BBIO)

Equity Research

June 28, 2026

Within the past twelve months, BridgeBio Pharma, Inc. has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking

services are being or have been provided.

Within the past twelve months, Jefferies Financial Group Inc. and/or its affiliates received compensation for products and services other than investment banking

services from non-investment banking, securities related compensation for client services it provided to Ascendis Pharma A/S.

Within the past twelve months, Ascendis Pharma A/S has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking

Explanation of Jefferies Ratings

Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of 15% or more within a 12-month period.

Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus 15% or minus 10% within a 12-month period.

Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus 10% or less within a 12-month period.

The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below $10 is 20% or more within a 12-

month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently

below $10, the expected total return (price appreciation plus yield) is plus or minus 20% within a 12-month period. For Underperform rated securities with an